Document 0439
 DOCN  M9650439
 TI    Effects of isoniazid treatment on human lymphocyte proliferative
       response, lymphocyte subsets and natural killer cell activity.
 DT    9605
 AU    Ravn P; Linnet J; Klokker M; Pedersen BK; Department of Infectious
       Diseases, Rigshospitalet, Copenhagen,; Denmark.
 SO    Immunopharmacology. 1995 Sep;30(3):247-53. Unique Identifier : AIDSLINE
       MED/96128558
 AB    The effect of isoniazid on proliferative response, natural killer (NK)
       cell activity and lymphocyte subset distribution of blood mononuclear
       cells (BMNC) was investigated. To evaluate the effect of treatment with
       isoniazid in pharmacologic concentrations, twenty healthy
       HIV-seronegative volunteers were randomized into two groups: one group
       received isoniazid tablets plus pyridoxin tablets once a day for 30
       days, the other group received pyridoxin only. Blood samples were
       collected on day 0 and day 30. Inhibition of the PHA-induced
       proliferative response was demonstrated in lymphocyte cultures from
       isoniazid-treated volunteers (p < 0.001). However, no effect was seen on
       the IL-2- or antigen (PPD)-induced proliferative response or the NK cell
       activity of isolated BMNC. Inhibition of the PHA-induced proliferative
       response could not be related to changes in the distribution of CD3+,
       CD4+, CD8+, CD14, or CD19+ lymphocyte subsets. The effects, in vitro,
       were investigated by addition of isoniazid to cultures of BMNC isolated
       from either HIV-seroposive or HIV-seronegative donors who did not
       receive any treatment. We found that isoniazid did not influence the
       mitogen- or antigen-stimulated proliferative response or the NK cell
       activity.
 DE    Adult  Antitubercular Agents/*PHARMACOLOGY  Female  Human
       Isoniazid/*PHARMACOLOGY  Killer Cells, Natural/*DRUG EFFECTS  Lymphocyte
       Subsets/*DRUG EFFECTS  Lymphocyte Transformation/*DRUG EFFECTS  Male
       Pyridoxine/PHARMACOLOGY  Support, Non-U.S. Gov't  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).